Physician profile
Olivia Hightower
NPI 1528228541
$22,794.05
in general payments reported to CMS, 2019-2025
90 companies · $4,133 in 2025
The $4,133 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,898 · 2020: $1,905 · 2021: $3,273 · 2022: $3,319 · 2023: $3,839 · 2024: $4,426 · 2025: $4,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $167 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,129.63 |
| Long Term Medical Supply Or Device Loan | $166.66 |
| Education | $102.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,224.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,891.80 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $1,389.68 | 2019-2025 | Phesgo, Tecentriq, Polivy |
| Astrazeneca Pharmaceuticals Lp | $1,218.95 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Janssen Biotech, INC. | $1,017.44 | 2019-2025 | Erleada, Akeega, Balversa |
| Eisai INC. | $1,013.90 | 2019-2025 | |
| Lilly USA, LLC | $831.75 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $786.32 | 2020-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $718.33 | 2019-2025 | Opdivo |
| Amgen INC. | $701.40 | 2019-2023 | Lumakras |
| Celgene Corporation | $679.90 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $670.66 | 2019-2025 | |
| Incyte Corporation | $669.69 | 2019-2025 | Monjuvi, Jakafi |
| Gilead Sciences, INC. | $391.80 | 2022-2025 | Trodelvy |
| Exelixis INC. | $382.21 | 2019-2025 | Cabometyx |
Show all 90 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.